Superworth

Axsome Therapeutics EPS AXSM

Diluted earnings per share by quarter and over the last twelve months, from 2015.

Last 12 months, to Jun 30, 2026
−$3.75
Latest quarter, Q2 FY26
−$0.99
Fiscal year 2025
−$3.69

Axsome Therapeutics' earnings per share was −$3.75 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.99.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$3.69n/a
FY2024−$5.99n/a
FY2023−$5.20n/a
FY2022−$4.57n/a
FY2021−$3.47n/a
FY2020−$2.77n/a
FY2019−$2.00n/a
FY2018−$1.14n/a
FY2017−$1.29n/a
FY2016−$1.43n/a
FY2015−$1.02n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.99n/a−$3.75
Q1 FY26−$1.26n/a−$3.73
Q4 FY25−$0.56n/a−$3.69
Q3 FY25−$0.94n/a−$4.67
Q2 FY25−$0.97n/a−$5.07
Q1 FY25−$1.22n/a−$5.77
Q4 FY24−$1.54n/a−$5.99
Q3 FY24−$1.34n/a−$6.53
Q2 FY24−$1.67n/a−$6.51
Q1 FY24−$1.44n/a−$6.38
Q4 FY23−$2.08n/a−$5.20
Q3 FY23−$1.32n/a−$4.53

Against its peers

Companies in Drug Manufacturers - General nearest Axsome Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
AXSMAxsome Therapeutics−$3.75
ALKSAlkermes plc.$0.38−82% a year
TGTXTG Therapeutics$2.74+641% a year
AMRXAmneal Pharmaceuticals$0.49+4800% a year
PTGXProtagonist Therapeutics$1.03+47% a year
CORTCorcept Therapeutics$0.42−63% a year
LGNDLigand Pharmaceuticals$9.40
KNSAKiniksa Pharmaceuticals International$0.97+2325% a year
BMRNBiomarin Pharmaceutical$0.37−89% a year
JAZZJazz Pharmaceuticals$14.62
INDVIndivior Pharmaceuticals$2.78+227% a year
Peer median$1.00

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Axsome Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.